Literature DB >> 26768689

Mutation status of essential thrombocythemia and primary myelofibrosis defines clinical outcome.

Julia Asp1, Björn Andréasson2, Ulrika Hansson3, Carina Wasslavik4, Johanna Abelsson5, Peter Johansson2, Lars Palmqvist6.   

Abstract

Entities:  

Keywords:  chronic myeloproliferative disorders; cytogenetics and molecular genetics; laboratory hematology

Mesh：

Substances：

Year:  2016        PMID： 26768689      PMCID： PMC5004407          DOI： 10.3324/haematol.2015.138958

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  13 in total

1.  Characterization of 35 new cases with four different MPLW515 mutations and essential thrombocytosis or primary myelofibrosis.

Authors:  Susanne Schnittger; Ulrike Bacher; Claudia Haferlach; Dietrich Beelen; Peter Bojko; Dieter Bürkle; Robert Dengler; Andrea Distelrath; Michael Eckart; Robert Eckert; Stefan Fries; Jan Knoblich; Georg Köchling; Hans-Peter Laubenstein; Petro Petrides; Manfred Planker; Rudolf Pihusch; Rudolf Weide; Wolfgang Kern; Torsten Haferlach
Journal:  Haematologica       Date:  2008-11-23       Impact factor: 9.941

2.  Characteristics and clinical correlates of MPL 515W>L/K mutation in essential thrombocythemia.

Authors:  Alessandro M Vannucchi; Elisabetta Antonioli; Paola Guglielmelli; Alessandro Pancrazzi; Vittoria Guerini; Giovanni Barosi; Marco Ruggeri; Giorgina Specchia; Francesco Lo-Coco; Federica Delaini; Laura Villani; Silvia Finotto; Emanuele Ammatuna; Renato Alterini; Valentina Carrai; Gloria Capaccioli; Simonetta Di Lollo; Vincenzo Liso; Alessandro Rambaldi; Alberto Bosi; Tiziano Barbui
Journal:  Blood       Date:  2008-06-02       Impact factor: 22.113

Review 3.  Molecular diagnostics of myeloproliferative neoplasms.

Authors:  Stephen E Langabeer; Hajnalka Andrikovics; Julia Asp; Beatriz Bellosillo; Serge Carillo; Karl Haslam; Lasse Kjaer; Eric Lippert; Olivier Mansier; Elisabeth Oppliger Leibundgut; Melanie J Percy; Naomi Porret; Lars Palmqvist; Jiri Schwarz; Mary F McMullin; Susanne Schnittger; Niels Pallisgaard; Sylvie Hermouet
Journal:  Eur J Haematol       Date:  2015-05-18       Impact factor: 2.997

4.  Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence.

Authors:  Giulio Genovese; Anna K Kähler; Robert E Handsaker; Johan Lindberg; Samuel A Rose; Samuel F Bakhoum; Kimberly Chambert; Eran Mick; Benjamin M Neale; Menachem Fromer; Shaun M Purcell; Oscar Svantesson; Mikael Landén; Martin Höglund; Sören Lehmann; Stacey B Gabriel; Jennifer L Moran; Eric S Lander; Patrick F Sullivan; Pamela Sklar; Henrik Grönberg; Christina M Hultman; Steven A McCarroll
Journal:  N Engl J Med       Date:  2014-11-26       Impact factor: 91.245

5.  Somatic mutations of calreticulin in myeloproliferative neoplasms.

Authors:  Thorsten Klampfl; Heinz Gisslinger; Ashot S Harutyunyan; Harini Nivarthi; Elisa Rumi; Jelena D Milosevic; Nicole C C Them; Tiina Berg; Bettina Gisslinger; Daniela Pietra; Doris Chen; Gregory I Vladimer; Klaudia Bagienski; Chiara Milanesi; Ilaria Carola Casetti; Emanuela Sant'Antonio; Virginia Ferretti; Chiara Elena; Fiorella Schischlik; Ciara Cleary; Melanie Six; Martin Schalling; Andreas Schönegger; Christoph Bock; Luca Malcovati; Cristiana Pascutto; Giulio Superti-Furga; Mario Cazzola; Robert Kralovics
Journal:  N Engl J Med       Date:  2013-12-10       Impact factor: 91.245

Review 6.  The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes.

Authors:  James W Vardiman; Jüergen Thiele; Daniel A Arber; Richard D Brunning; Michael J Borowitz; Anna Porwit; Nancy Lee Harris; Michelle M Le Beau; Eva Hellström-Lindberg; Ayalew Tefferi; Clara D Bloomfield
Journal:  Blood       Date:  2009-04-08       Impact factor: 22.113

7.  Distinct clinical characteristics of myeloproliferative neoplasms with calreticulin mutations.

Authors:  Hajnalka Andrikovics; Tunde Krahling; Katalin Balassa; Gabriella Halm; Andras Bors; Magdalena Koszarska; Arpad Batai; Janos Dolgos; Judit Csomor; Miklos Egyed; Andrea Sipos; Peter Remenyi; Attila Tordai; Tamas Masszi
Journal:  Haematologica       Date:  2014-06-03       Impact factor: 9.941

8.  Prognostic significance of ASXL1, JAK2V617F mutations and JAK2V617F allele burden in Philadelphia-negative myeloproliferative neoplasms.

Authors:  Ipek Yonal-Hindilerden; Aynur Daglar-Aday; Basak Akadam-Teker; Ceylan Yilmaz; Meliha Nalcaci; Akif Selim Yavuz; Deniz Sargin
Journal:  J Blood Med       Date:  2015-06-01

9.  Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2.

Authors:  J Nangalia; C E Massie; E J Baxter; F L Nice; G Gundem; D C Wedge; E Avezov; J Li; K Kollmann; D G Kent; A Aziz; A L Godfrey; J Hinton; I Martincorena; P Van Loo; A V Jones; P Guglielmelli; P Tarpey; H P Harding; J D Fitzpatrick; C T Goudie; C A Ortmann; S J Loughran; K Raine; D R Jones; A P Butler; J W Teague; S O'Meara; S McLaren; M Bianchi; Y Silber; D Dimitropoulou; D Bloxham; L Mudie; M Maddison; B Robinson; C Keohane; C Maclean; K Hill; K Orchard; S Tauro; M-Q Du; M Greaves; D Bowen; B J P Huntly; C N Harrison; N C P Cross; D Ron; A M Vannucchi; E Papaemmanuil; P J Campbell; A R Green
Journal:  N Engl J Med       Date:  2013-12-10       Impact factor: 91.245

10.  JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes.

Authors:  Elisa Rumi; Daniela Pietra; Virginia Ferretti; Thorsten Klampfl; Ashot S Harutyunyan; Jelena D Milosevic; Nicole C C Them; Tiina Berg; Chiara Elena; Ilaria C Casetti; Chiara Milanesi; Emanuela Sant'antonio; Marta Bellini; Elena Fugazza; Maria C Renna; Emanuela Boveri; Cesare Astori; Cristiana Pascutto; Robert Kralovics; Mario Cazzola
Journal:  Blood       Date:  2013-12-23       Impact factor: 22.113
View more
  8 in total

1.  Positive impact of molecular analysis on prognostic scores in essential thrombocythemia: a single center prospective cohort experience.

Authors:  Damien Luque Luque Paz; Olivier Mansier; Jérémie Riou; Carole Conejero; Lydia Roy; Célia Belkhodja; Valérie Ugo; Stéphane Giraudier
Journal:  Haematologica       Date:  2018-10-18       Impact factor: 9.941

2.  The poor outcome in high molecular risk, hydroxycarbamide-resistant/intolerant ET is not ameliorated by ruxolitinib.

Authors:  Jennifer M O'Sullivan; Angela Hamblin; Christina Yap; Sonia Fox; Rebecca Boucher; Anesh Panchal; Samah Alimam; Helene Dreau; Kieran Howard; Pauline Ware; Nicholas C P Cross; Mary Frances McMullin; Claire N Harrison; Adam J Mead
Journal:  Blood       Date:  2019-12-05       Impact factor: 22.113

Review 3.  Cardiovascular Disease in Myeloproliferative Neoplasms: JACC: CardioOncology State-of-the-Art Review.

Authors:  Orly Leiva; Gabriela Hobbs; Katya Ravid; Peter Libby
Journal:  JACC CardioOncol       Date:  2022-06-21

4.  A patient with a germline GATA2 mutation and primary myelofibrosis.

Authors:  Cyrill V Rütsche; Eugenia Haralambieva; Veronika Lysenko; Stefan Balabanov; Alexandre P A Theocharides
Journal:  Blood Adv       Date:  2021-02-09

5.  Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial.

Authors:  Srdan Verstovsek; Ruben A Mesa; Jason Gotlib; Vikas Gupta; John F DiPersio; John V Catalano; Michael W N Deininger; Carole B Miller; Richard T Silver; Moshe Talpaz; Elliott F Winton; Jimmie H Harvey; Murat O Arcasoy; Elizabeth O Hexner; Roger M Lyons; Ronald Paquette; Azra Raza; Mark Jones; Deanna Kornacki; Kang Sun; Hagop Kantarjian
Journal:  J Hematol Oncol       Date:  2017-02-22       Impact factor: 17.388

6.  Coexistent Breast Cancer and Essential Thrombocythemia: How We Addressed the Therapeutic Challenges.

Authors:  Karan Seegobin; Bharatsinh Gharia; Satish Maharaj; Lara Zuberi
Journal:  Case Rep Hematol       Date:  2018-08-12

7.  Isolated ten-eleven translocation 2 positive in triple negative essential thrombocythemia: Case report and literature review.

Authors:  Rehab Y Al-Ansari; Dena Al Otaibi; Nourah Al Hudaithi; Leena Abdalla
Journal:  SAGE Open Med Case Rep       Date:  2021-07-15

Review 8.  Next Generation Sequencing in MPNs. Lessons from the Past and Prospects for Use as Predictors of Prognosis and Treatment Responses.

Authors:  Vibe Skov
Journal:  Cancers (Basel)       Date:  2020-08-06       Impact factor: 6.639
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.